Abslracl-In this paper we apply the Fractional Differencing Autoregressive Moving Average (FARMA) model for ultrasonic breast tissue characterization using RF echo signals. We present estimation techniques to extract the model parameters, namely features, for classification purposes and tissue characterization. Along with the model parameters, we use patient age information as an additional feature to improve ROC results. We evaluate the performance of the proposed method using in vivo ultrasound breast images with benign and malignant tumors.
I. INTRODUCTION
The information contained in-ultrasound RF echo can he used to distinguish between tumors thorough tissue characterization features Transducer response is modeled as an ARMA process, and tissue response is modeled as a fractional differencing process (FDM), leading to a FARMA process for RF echo.
Transducer response, i.e., ARMA parameters, are estimated using phantom data based on the final prediction error (FDE) and residual time series methods. Next, the transducer response is deconvolved from the RF echo and the FD parameter d is estimated from the resulting signal, based on a log periodogm technique. The sample mean and the variance of the parameter d from the inside..and the outside of the suspected tumor are estimated next using multiple adjacent scanlines. A feature vector based on parameter d and patient age is formed. Classification is performed using a quadrature classifier under Gaussian assumption. Finally, the receiver operator characteristics (ROC) for the proposed method is derived using 60 in vivo ultrasound breast images containing both benign and malignant tumors. The resulting ROC has an area of 0.83, shows that the proposed method can be used effectively to differentiate between benign and malignant breast tumors. 
A(z-')z(R)
is a white Gaussian noise sequence with-zem. mean and unit variance, t -' is unit delay operator, A ( z -l ) , and B(z-') are the autoregressive and moving-average polynomials of orders p and q. respectively. For each B-scan image, 30 scanlines from the inside and outside the tumor region were taken with data lengths of 1x128, and each of these scanlines were used to estimate the fractional differencine Darameter d. Hence. we have 30
ESTIMATION
In ultrasonic applications, the RF echo scattered from tissue is modeled as a convolution integral of the ultrasonic pulse and the scattering structure as follows: 
IV. CLASSIFICATION OF B-SCAN IMAGES FOR TISSUE CHARACTERIZATION
In [9] area under the ROC was calculated as 0.79 with classification using only the fractional differencing parameter d. Classification quality can be improved by including patient age information as a second feature. Assuming that patient age and d parameter are independent and Gaussian distributed, a quadratic classifier can be used to classify benign and malignant tissues. IS objects both f " malignant and benign classes were chosen randomiy as the training set and classification discriminant was computed for the quadratic classifier. In Figure 2 , results for the classification are displayed and plotted. The classes were plotted in a scatter diagram together with the discriminant and the cuwe for the quadratic classifier. The ROC curve, given in Figure 3 , was obtained by plotting the probability of false alarm versus the probability of detection. Probability of defection is the ratio between the number of correct malignant decisions and total number of malignant cases. The probability of false alarm is the ratio between the number of incorrect benign decisions and total number V. CONCLUSION In this paper, we modeled the RF echo as a FARMA process.
We showed that the FARMA model parameters can be used to discriminate between benign and malignant tumors. The ROC analysis based on 60 in vivo B-scan images shows that the proposed method yields results that are comparable to most methods reported in the literature. In our futurc work, we will include morphological features such as tumor size and smoothness to improve our ROC results. ACKNOWLEDGMENT This work is supported in part by the National Institutes of Health, National Cancer Institute, Grant Number: CA 52823:
